AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06323785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active whole-body hyperthermia
Description: Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
Study NCT04891705 — intervention group
Intervention type: DEVICE
Intervention: Lung Ultrasound Scan
Description: Ultrasound scan of subjects in up to 14 lung zones
Study NCT05686798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Description: Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
Study NCT06323785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham whole-body hyperthermia
Description: Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
Study NCT01981668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
Study NCT05926453 — intervention group
Intervention type: OTHER
Intervention: Maximal cardiorespiratory exercise test
Description: previously described
Study NCT05872191 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention to be administered, only collection of data through various tests and questionnaires.
Study NCT05484414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-3D (diethylamide)
Description: SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Study NCT05484414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Study NCT04522648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective surveillance
Description: A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
Study NCT05637034 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-F2 PET/CT and 18F-FDG
Description: Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
Study NCT05816915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
Study NCT06128018 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical gastrojejunostomy (S-GJ)
Description: Surgical gastro-jejunostomy
Study NCT06128018 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-guided gastrojejunostomy (EUS-GJ)
Description: Endoscopic Ultrasound guided gastro-jejunostomy
Study NCT06420388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine Gel
Description: The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications.
Study NCT06420388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water-based Lubricant Gel (K-Y Gel)
Description: The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
Study NCT06420388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Postoperative Analgesics
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous
Study NCT06420388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Postoperative Analgesics
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous
Study NCT05006378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Tea
Description: Chamomile tea bags consumed by subjects as described in study arms section.
Study NCT05006378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile Extract Capsule
Description: Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section.
Study NCT05006378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsules consumed by subjects as described in Placebo Comparator study arms section.
Study NCT04756622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
Study NCT05570552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth based behavioral change communication intervention
Description: We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
Study NCT05042817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg morphine
Description: The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
Study NCT05042817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: NaCl 0.9%
Study NCT05042817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg prilocaine + 2.5 mcg sufentanil
Description: 50 mg prilocaine + 2.5 mcg sufentanil
Study NCT05042817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg prilocaine + 2.5 mcg sufentanil
Description: 50 mg prilocaine + 2.5 mcg sufentanil
Study NCT05042817 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bilateral transverse abdominal plane block
Description: 20 mL of ropicavaine 0.375% on each side
Study NCT04447508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants receive one on one motivational interviewing and participate in a group exercise class virtually.
Description: Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
Study NCT05432336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NGS for endohtalmitis / Multiplex PCR for keratitis
Description: For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples
Study NCT05183529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitals Monitoring Pill System
Description: The Celero Vitals Monitoring Pill (VM Pill) uses 3 axis accelerometry to measure physiological signals from within the GI tract.
Study NCT04632459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus ramucirumab
Description: Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles.
Study NCT05191719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Comparator, current gold standard
Study NCT05191719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Comparator, current gold standard
Study NCT05191719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotomy
Description: Surgical procedure
Study NCT05191719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotomy
Description: Surgical procedure
Study NCT06392035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education, web-based education
Description: Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
Study NCT04776928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push reports
Description: Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc.
Study NCT05173077 — intervention group
Intervention type: PROCEDURE
Intervention: Identification of specific VOCs in CRC tissue surgery material
Description: Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
Study NCT05173077 — intervention group
Intervention type: OTHER
Intervention: Secondary validation study in general CRC screening settings
Description: Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results.
Study NCT05173077 — intervention group
Intervention type: DEVICE
Intervention: Breath sampling for VOC detection
Description: Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
Study NCT05173077 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Serum, plasma sampling for group description and stratification.
Study NCT05173077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota testing
Description: Faecal samples for microbiota testing.
Study NCT05173077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Colonoscopy will be used only according to the clinical indications.
Study NCT05589896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ossium HPC Marrow, Bone Marrow Transplant
Description: Hematopoetic Cell Transplantation
Study NCT05589896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-transplant conditioning - Myeloablative (MAC)
Description: Regimen A or Regimen B
Study NCT05589896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-transplant conditioning - Reduced Intensity (RIC)
Description: Regimen C
Study NCT05589896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-transplant treatment
Description: Post-transplant treatment
Study NCT05089578 — intervention group
Intervention type: OTHER
Intervention: focus interview
Description: The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes.
Study NCT06286917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV initiation in patients with ALS
Description: NIV initiation according to standard care
Study NCT05945238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Program
Description: T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
Study NCT05013216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: Patients at high risk of developing pancreatic cancer.
Description: 1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC
Study NCT05013216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Description: Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
Study NCT05874232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Program through Heartfulness
Description: A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
Study NCT06127277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Next4You
Description: Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
Study NCT06127277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Next4You
Description: Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
Study NCT05406414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic sleep and circadian treatment
Description: The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems
Study NCT05406414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active waitlist control group
Description: The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
Study NCT05427435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marshall ethanolisation
Description: Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
Study NCT05550636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT05550636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study NCT05667662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
Study NCT05667662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with 11.8 mg total powder (excipients only)
Study NCT05324319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26COVS1
Description: Heterologous vaccination
Study NCT05324319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAdOx1 SARS2 Vaccine
Description: Heterologous vaccination
Study NCT05324319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNT162B2
Description: Homologous vaccination
Study NCT05324319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Homologous vaccination
Study NCT06249516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation training
Description: Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
Study NCT06249516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Description: Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
Study NCT06249516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active Breathing Exercises
Description: Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.